Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

from Yahoo Finance https://ift.tt/2M1KPF5

Novartis’s gene therapy unit AveXis has signed a manufacturing deal to help produce a novel genetic COVID-19 vaccine candidate being developed by U.S. researchers in Massachusetts, a spokeswoman for the Swiss drugmaker confirmed on Thursday. Massachusetts General Hospital and Massachusetts Eye and Ear are developing a vaccine candidate that relies on adeno-associated viral (AAV) vector technology to produce immunity. AveXis, which makes Novartis’s $2.1 million-per-patient gene therapy Zolgensma for the hereditary disease spinal muscular atrophy, is contributing technology, expertise and its manufacturing supply chain at no cost, it said.

from Yahoo Finance https://ift.tt/3c9myYb

from Yahoo Finance https://ift.tt/2ZLZhJu